CompletedNCT00191906
Atomoxetine compared with placebo for ADHD and reading difficulties
About this title
Read the official source — NCT00191906Medication studyAges 8–12Belgium + Netherlands
Understand this study
Who was this study for?
Listed age limits: 8 years to 12 years.
- Listed locations
- Ghent and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateApril 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 121
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium, Netherlands
- Age range
- From 8 Years to 12 Years
- Official registry ID
- NCT00191906
- Official title
Show the full official title
A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ghent, Belgium · Almere Stad, Netherlands · Amsterdam, Netherlands
2 more locations
- Breda, Netherlands
- Vught, Netherlands
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride and placebo.
Who was this study for?
Listed age limits: 8 years to 12 years.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...